Dr. Kealey has served as NeuroSigma’s CEO since January of 2022. Dr. Kealey has been with NeuroSigma since 2011, having previously served as our President, Vice President of Advanced Development and Medical Affairs, and Manager of Business Development. In these roles, Dr. Kealey spearheaded NeuroSigma’s regulatory submissions that ultimately led to FDA clearance of the Monarch eTNS System for pediatric ADHD. He also helped introduce eTNS to major academic centers and clinics throughout the United States, European Union and Canada. In these roles he interfaced with key opinion leaders in the field to convey the science behind eTNS and how it may fit into their current clinical practice. During his time at NeuroSigma Dr. Kealey has been a principal investigator on three National Institutes of Health (NIH) grants and is coauthor on 17 peer reviewed publications and three book chapters. He is also an inventor on 12 issued and pending U.S. patents. Prior to joining NeuroSigma, Dr. Kealey was a resident physician in the UCLA Department of Surgery from 2007 to 2011. During his time at UCLA, Dr. Kealey was responsible for all aspects of the care of surgical patients ranging from outpatient procedures to critically ill patients in the intensive care unit. From 2009 to 2011, Dr. Kealey completed a post-doctoral research program at UCLA’s Center for Advanced Surgical and Interventional Technology (CASIT) where he performed research and development on novel medical devices.
Dr. Kealey earned his B.S. in Biochemistry and Molecular Biology from the University of Wisconsin – Madison and his M.D. from the University of Iowa Carver College of Medicine.